FDA Business Process Improvement

The Food and Drug Administration (FDA) intends to establish a GSA BPA with McKinsey and Company to provide professional Business Process Improvement (BPI) and strategic management consulting services. The goal of this initiative is to implement a vigorous and continuous business management and quality improvement process for the policies and practices that govern the management of our resources. Our goal is to ensure that the decisions made by the FDA can be tracked through and supported by clearly communicated and documented processes in an integrated and transparent manner. Particular emphasis has been placed on food protection; import safety; pre-market application and associated approval processed; and post-market risk surveillance and communication. The FDA intends to include open market items on the award to McKinsey and Company. The open market items include any travel needed for the successful completion of individual orders placed under the BPA. The travel will be at a not to exceed amount determined by the Government in accordance with GSA travel rates. The FDA's original requirement was competed among four GSA schedule holders. Only one, McKinsey and Company, submitted a bid, which included open market items needed for this requirement. This notice of intent is not a request for competitive quotations and no solicitation document is available. However, any firm that believes it can meet these requirements may give notification to the Contract Specialist by 8:00am eastern time on March 26, 2010. Interested firms must furnish supporting evidence with sufficient detail to demonstrate its ability to comply with the requirement described above. Interested firms may email the information to the Contract Specialist, U.S. Food and Drug Administration, Attn: Keith Austin at keith.austin@fda.hhs.gov. The FDA will review all responses received; however, the Government retains the sole discretion not to further compete the proposed acquisition based on responses to this notice. If the FDA does not receive any responses, the FDA will proceed with BPA award to: McKinsey and Company